Welcome to our dedicated page for Arteris SEC filings (Ticker: AIP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Arteris, Inc. filings document a semiconductor technology business built around System IP for SoC and chiplet design. Its 8-K reports cover quarterly and annual operating results, financial-condition updates, guidance exhibits, customer shipment milestones, royalty trends and product portfolio disclosures for network-on-chip interconnect IP, SoC integration automation software and hardware security assurance.
The company’s proxy materials cover board elections, executive compensation, equity incentive arrangements and stockholder voting matters. They also describe governance and business context for Arteris’ markets, including automotive, artificial intelligence and machine learning, 5G communications, data centers, edge computing, enterprise and consumer electronics.
Bayview Legacy, LLC, a 10% owner of Arteris, Inc., reported open‑market sales totaling 100,000 shares of common stock on August 3–4, 2026. The five indirect transactions, executed under a Rule 10b5‑1 trading plan adopted on December 12, 2025, used weighted‑average pricing, with underlying trade ranges from $28.17 to $32.48 per share. K. Charles Janac, Bayview’s manager, is deemed to have voting and dispositive power over these shares and has separately reported his beneficial ownership.
Arteris, Inc. director Saiyed Atiq Raza, through the Saiyed Atiq Raza and Nandini Saraiya 2012 Revocable Trust, sold a total of 70,000 common shares on August 3, 2026 in three open-market transactions at weighted average prices of $28.7765, $29.9898 and $30.3009 per share within stated price ranges. The sales were made pursuant to a Rule 10b5-1 trading plan adopted on November 7, 2025. A separate holding entry reports 4,703 common shares held directly.
Arteris, Inc. VP and General Counsel Paul L. Alpern exercised 4,000 incentive stock options at $0.56 per share on August 3, 2026, receiving 4,000 shares of common stock. The same day, he sold 600 and 3,400 shares at weighted-average prices of $29.11 and $30.1991 in transactions made pursuant to a Rule 10b5-1 trading plan adopted on February 23, 2026. Following the option exercise, 53,000 options from this grant remained outstanding.
Arteris, Inc. director, President and CEO K. Charles Janac reported indirect sales of 100,000 shares of common stock through Bayview Legacy, LLC on August 3–4, 2026. The shares were sold in multiple transactions at weighted-average prices of $28.7865, $29.9906, $30.3132, $31.9217 and $32.4149 per share under a Rule 10b5-1 trading plan adopted on December 12, 2025. Following these sales, he reports 175,148 shares held directly and 56,252 shares held indirectly via the Charles and Lydia Janac Trust.
AIP insider Paul Lawrence Alpern has filed to sell 18,500 shares of common stock on 08/03/2026, to be issued upon the cash exercise of stock options and listed on NASDAQ. The notice also lists recent sales under a Rule 10b5-1 trading plan, including 6,003 shares for $215,587.30 on 07/06/2026, 3,648 shares for $141,461.78 on 07/02/2026, 6,500 shares for $295,513.85 on 07/01/2026, and 12,502 shares for $450,285.78 on 06/01/2026.
Atiq Raza & N. Saraiya 2012 Revocable Trust, as reported owner of AIP common stock, filed to sell 70,000 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services, with an aggregate market value of $2,091,600, expected to be sold on or after August 3, 2026 on NASDAQ. The shares were acquired on December 28, 2020 via previously exercised stock options for cash. Over the past three months, the trust reported additional 10b5-1 sales of AIP common stock, including 70,000 shares for $3,176,978 on July 1, 2026, 20,839 shares for $779,174.38 on June 3, 2026, and 70,000 shares for $2,521,106 on June 1, 2026.
BlackRock, Inc. reports a passive ownership stake in Arteris, Inc. common stock on Schedule 13G. BlackRock and certain of its business units are deemed to beneficially own 2,884,824 shares of Arteris common stock, representing 6.2% of the class as of June 30, 2026.
BlackRock has sole voting power over 2,828,242 shares and sole dispositive power over 2,884,824 shares, with no shared voting or dispositive power. Various underlying clients have rights to dividends and sale proceeds, but no single client holds more than five percent of Arteris’s total outstanding common shares.
Arteris, Inc. director, President and CEO K. Charles Janac reported open-market sales of common stock mainly through indirect holdings. On July 6, 2026, entities associated with him sold an aggregate of 136,655 shares of Arteris common stock in several transactions.
The reported sales, including those by Bayview Legacy, LLC and direct holdings, occurred at weighted average prices between roughly $35 and $37 per share. According to the disclosure, these trades were executed under a Rule 10b5-1 trading plan adopted on December 12, 2025, and Janac continues to hold substantial direct and indirect positions, including shares in the Charles and Lydia Janac Trust.
Bayview Legacy, LLC, a 10% owner of Arteris, Inc. (AIP), reported open-market sales of a total of 125,976 shares of common stock on July 6, 2026. The sales were executed in three tranches at weighted average prices of $35.065, $36.2365, and $37.0705 per share.
The trades were made pursuant to a Rule 10b5-1 trading plan adopted by K. Charles Janac, the manager of Bayview Legacy, LLC, on December 12, 2025. Janac is deemed to have voting and dispositive power over the shares held by Bayview Legacy, and he has separately filed a Form 4 reflecting the same transactions.
Arteris, Inc. VP and General Counsel Paul L. Alpern reported selling 6,003 shares of common stock in open-market transactions on July 6, 2026. The sales were executed at weighted average prices in ranges between $34.65 and $37.57 per share under a pre-arranged Rule 10b5-1 trading plan. Following these transactions, he directly holds 70,733 shares of Arteris common stock.